

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Costa Mesa, CA – August 27-28, 2021

Conference Location	Avenue of the Arts Hotel 3350 Avenue of the Arts Costa Mesa, CA	Phone: (714) 751-5100 https://www.marriott.com/hotels/travel/csmtx-avenue-of-the-arts-costa-mesa-a-tribute-portfolio-hotel
----------------------------	--	---

Parking at the Conference	Discounted Self-Parking of \$8,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rate
----------------------------------	---

Driving Directions	Follow I-405 N or S to Bristol Street in Costa Mesa. Continue on Bristol Street. Turn right on Anton Blvd. Turn left on Avenue of the Arts and the hotel will be on your left. A limited number of hotel guest rooms are available the night of August 27 for \$149 plus taxes
---------------------------	---

Seminar Agenda and Syllabus Information	Registration begins at 7:30 a.m. in the Cole Porter Ballroom . Please check signage for any last-minute room changes. The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge.
--	---

A limited number of guest rooms have been reserved on the night of August 27 at \$149 plus taxes

Day 1	Registration and View Exhibits
12:00 -1:00pm	
1:00 pm	Opening Comments and Pre-Test
1:15 pm	Viral Hepatitis, Discovery of HCV and Its Natural History
2:00 pm	Hepatitis C: Update on Diagnostics Hepatitis C: Update on Treatment
3:00 pm	Break and View exhibits
3:15 pm	Hepatitis B: Epidemiology, Natural History and Testing
3:45 pm	Anti-viral Therapies for HBV
4:40pm	Delta Hepatitis and Hepatitis E Update from AASLD and EASL Case Studies 1 and 2 –HIV/HCV Co-infection; Infections in persons who inject drugs.
5:10 pm	Product Presentation, Exhibitor Showcase and Reception
6:30 pm	Day 1 concludes
Day 2	Breakfast and View Exhibits
7:30 am	

8:00 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant Liver Transplantation Case Study 3 – Cirrhosis and Encephalopathy
8:55 am	Hepatocellular Carcinoma (HCC)
9:25 am	Hepatocellular Carcinoma: New Systemic Treatment Options Case Study 4– Diagnosis and Treatment of Hepatocellular Carcinoma
10:15 am	Break & View Exhibits
10:30 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis
11:15 am	Viral Hepatitis Updates <ul style="list-style-type: none"> • The reemergence of Hepatitis A and Alcoholic liver disease
11:45 am	SARS-COV-2 in Liver Disease
12:15 pm	Luncheon Presentation
1:15 pm	NAFLD, LAL-D and NASH
2:10 pm	Break & View Exhibits
2:25 pm	NASH Treatments in Practice and in Development
3:30 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 3:45pm

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1205. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

**Your
Seminar
Faculty**



TIMOTHY MORGAN, MD

Dr. Timothy Morgan is Chief of Gastroenterology at the VA Long Beach Healthcare System and Professor of Medicine at the University of California, Irvine. Dr. Morgan is the Director of the VA National Hepatitis C Resource Center which oversees programs to improve diagnosis and treatment of hepatitis C, and improve care for patients with cirrhosis, across the VA healthcare system. He is a co-chair of the AASLD-IDSA hepatitis C treatment guideline committee and chair of the VA HCTV treatment guidelines. He has been an investigator on clinical trials in hepatitis C for the past 25 years, and in alcoholic hepatitis and alcoholic cirrhosis for the past 30 years. He is currently the Principal Investigator on the Southern California Alcoholic Hepatitis Consortium, an NIH-funded consortium to evaluate new treatments and to better understand the pathophysiology of alcoholic hepatitis.



MAZEN NOUREDDIN, MD, MHSC,

Dr. Mazen Nouredin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World report. His focus is on clinical and translational research in the area of NAFLD.

Dr. Nouredin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, transient elastography, and magnetic resonance imaging techniques. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He was one of the authors who established MRI-PDFF as a precise biomarker for measurement of liver fat in patients with NAFLD/ NASH.



TAMMY HARPER, NP-C

Tammy Harper received her undergraduate degree at Union University in Tennessee and her Masters Degree in nursing from the University of California in Los Angeles. Tammy Harper joined in 2013, after 14 years of practicing internal medicine. Her clinical interest and expertise are in chronic liver disease and liver transplantation.

Tammy has participated in research studies related to Hepatitis C infections, including Detection of Occult Hepatitis C virus Infection in Patients Who Achieved Sustained Virologic Response to Direct Acting Antiviral Agents for Recurrent Infection After Liver Transplantation. Published in The Journal of Gastroenterology in 2017, and abstract accepted to AASLD in 2016.

Professionally, Tammy is an associate member of the American Association for the Study of Liver Disease, and the Co-Chair of the Southern California Society of Gastroenterology Nurses Course.
